Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This article overviews the recommended dosing strategies for the treatment of schizophrenia patients using the recently FDA-approved once-monthly long-acting injectable atypical antipsychotic, paliperidone palmitate. METHODS: Using pharmacokinetic (PK), efficacy and safety data from clinical trials and a comprehensive population PK simulation model, dosing recommendations for paliperidone palmitate have been generated. RESULTS: The recommended initiation regimen is 150 mg eq. paliperidone palmitate (234 mg) on Day 1 followed by 100 mg eq. paliperidone palmitate (156 mg) on Day 8, each administered into the deltoid muscle, using a 1-inch 23 gauge (G) needle in those <90 kg and a 1.5-inch 22 G needle in those > or =90 kg. No oral supplementation is required. Monthly maintenance doses of paliperidone palmitate range from 25-150 mg eq. (39-234 mg; recommended dose of 75 mg eq. [117 mg]) injected into the deltoid (using weight-adjusted needle) or gluteal (using 1.5 inch 22 G needle) muscle. The Day 8 dose may be administered +/-2 days and monthly doses +/-7 days, without a clinically significant impact on plasma concentrations. In patients with mild renal impairment (creatinine clearance [CrCL]: 50-80 mL/min), dosage should be adjusted. No dose adjustment is required in patients with mild or moderate hepatic impairment; no data currently exist regarding severe hepatic impairment. Elderly patients with normal renal function should receive the same dosage as younger adult patients with normal renal function. In the event of an age-related decline in CrCL, dosage should be adjusted accordingly. Paliperidone palmitate treatment can be initiated the day after discontinuing previous oral antipsychotic treatment. Paliperidone palmitate should be initiated at the next scheduled injection, and monthly thereafter, in patients switching from other long-acting injectable antipsychotics, including long-acting risperidone. CONCLUSIONS: These data provide practical guidance to clinicians on how to use paliperidone palmitate in adult patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Samtani, M. N., Vermeulen, A., & Stuyckens, K. (2009) · Clinical Pharmacokinetics · doi:10.2165/11316870-000000000-00000 · Cited by 170
Self-citationAbsorption, Metabolism, and Excretion of Paliperidone, a New Monoaminergic Antagonist, in Humans
Vermeir, M., Naessens, I., Remmerie, B., Mannens, G., Hendrickx, J., Sterkens, P., Talluri, K., Boom, S., Eerdekens, M., van Osselaer, N., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018275 · Cited by 158
Cited by
Merisko-Liversidge, E., & Liversidge, G. G. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.12.007 · Cited by 608
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & WFSBP Task force on Treatment Guidelines for Schizophrenia (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.739708 · Cited by 416
Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia
Leucht, S., Crippa, A., Siafis, S., Patel, M. X., Orsini, N., & Davis, J. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010034 · Cited by 301
Maintenance treatment with antipsychotic drugs for schizophrenia
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., & Davis, J. M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008016.pub2 · Cited by 290
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Metadata
- Authors
- Gopal, S., Gassmann-Mayer, C., Palumbo, J., Samtani, M. N., Shiwach, R., & Alphs, L.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 2009-12-10
- Volume
- 26
- Issue
- 2
- Pages
- 377-387
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2117764692
- Cited by
- 73
- References
- 2
- FWCI
- 3.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.